Cargando…

Therapeutic Strategies Targeting DUX4 in FSHD

Facioscapulohumeral muscular dystrophy (FSHD) is a common muscle dystrophy typically affecting patients within their second decade. Patients initially exhibit asymmetric facial and humeral muscle damage, followed by lower body muscle involvement. FSHD is associated with a derepression of DUX4 gene e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Gall, Laura, Sidlauskaite, Eva, Mariot, Virginie, Dumonceaux, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564105/ https://www.ncbi.nlm.nih.gov/pubmed/32906621 http://dx.doi.org/10.3390/jcm9092886

Ejemplares similares

DUX4 Expression in FSHD Muscles: Focus on Its mRNA Regulation
por: Sidlauskaite, Eva, et al.
Publicado: (2020)

Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
por: Joubert, Romains, et al.
Publicado: (2020)

RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy
por: Mariot, Virginie, et al.
Publicado: (2021)

A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020)

DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2021)

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2021)

Functional domains of the FSHD-associated DUX4 protein
por: Mitsuhashi, Hiroaki, et al.
Publicado: (2018)

The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression
por: Vanderplanck, Céline, et al.
Publicado: (2011)

Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts
por: Pandey, Sachchida Nand, et al.
Publicado: (2015)

Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes
por: Rashnonejad, Afrooz, et al.
Publicado: (2020)

DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
por: Klingler, Christian, et al.
Publicado: (2020)

MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy
por: Runfola, Valeria, et al.
Publicado: (2023)

DUX4 Binding to Retroelements Creates Promoters That Are Active in FSHD Muscle and Testis
por: Young, Janet M., et al.
Publicado: (2013)

Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)
por: Ansseau, Eugénie, et al.
Publicado: (2017)

PARP1 Differentially Interacts with Promoter region of DUX4 Gene in FSHD Myoblasts
por: Sharma, Vishakha, et al.
Publicado: (2016)

An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy
por: Cowley, Matthew V, et al.
Publicado: (2023)

Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model
por: Bosnakovski, Darko, et al.
Publicado: (2017)

DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation
por: Banerji, Christopher R S, et al.
Publicado: (2020)

Telomere Position Effect (TPE) Regulates DUX4 in Human Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Stadler, Guido, et al.
Publicado: (2013)

Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation
por: Homma, Sachiko, et al.
Publicado: (2015)

WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2023)

PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level
por: Banerji, Christopher R S, et al.
Publicado: (2019)

Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD
por: Himeda, Charis L., et al.
Publicado: (2020)

Author Correction: Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model
por: Bosnakovski, Darko, et al.
Publicado: (2018)

DUX4c Is Up-Regulated in FSHD. It Induces the MYF5 Protein and Human Myoblast Proliferation
por: Ansseau, Eugénie, et al.
Publicado: (2009)

Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4
por: Homma, Sachiko, et al.
Publicado: (2016)

Proximity ligation assay to detect DUX4 protein in FSHD1 muscle: a pilot study
por: Beermann, Mary Lou, et al.
Publicado: (2022)

Biphasic Myopathic Phenotype of Mouse DUX, an ORF within Conserved FSHD-Related Repeats
por: Bosnakovski, Darko, et al.
Publicado: (2009)

Asymmetric Bidirectional Transcription from the FSHD-Causing D4Z4 Array Modulates DUX4 Production
por: Block, Gregory J., et al.
Publicado: (2012)

Targeting the Polyadenylation Signal of Pre-mRNA: A New Gene Silencing Approach for Facioscapulohumeral Dystrophy
por: Marsollier, Anne-Charlotte, et al.
Publicado: (2018)

DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
por: Tassin, Alexandra, et al.
Publicado: (2013)

Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Jones, Takako I., et al.
Publicado: (2016)

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
por: Sarsons, Christopher D., et al.
Publicado: (2023)

Gene Editing to Tackle Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2022)

A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice
por: Kakimoto, Tetsuhiro, et al.
Publicado: (2023)

FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
por: Himeda, Charis L., et al.
Publicado: (2022)

Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2022)

Current Therapeutic Approaches in FSHD
por: Wang, Leo H., et al.
Publicado: (2021)

Persistent Fibroadipogenic Progenitor Expansion Following Transient DUX4 Expression Provokes a Profibrotic State in a Mouse Model for FSHD
por: Bosnakovski, Darko, et al.
Publicado: (2022)

BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells
por: Campbell, Amy E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_341s5sk8ea4t261hhh0vhqr5pu